Sigachi Industries Ltd Q2FY26 | ₹110 Cr Sales, ₹6.3 Cr Profit – The Pharma Supplier That Survived Fire, Fines, and a Fatal Year of Dust Explosions
1. At a Glance
Sigachi Industries Ltd – the cellulose specialist that quite literally turned to ashes and came back with a fireproof business plan. The stock trades at ₹39, down almost 15% YoY, after a year straight out of a corporate thriller — factory explosions, fatalities, insurance claims, and yet, a functioning profit.
With ₹110 crore revenue this quarter (down 11.6% QoQ) and a PAT of ₹6.3 crore (down 71% YoY), the company’s quarter looked like a cricket team batting after a power cut — technically on the field, but barely scoring. The firm, once a poster child for small-cap manufacturing efficiency, now faces a battle for reputation and recovery.
Still, its market cap of ₹1,489 crore, ROE of 13.5%, and ROCE of 15.5% show there’s business resilience hiding under all that soot. It operates in over 65 countries, exports two-thirds of its products, and maintains four certified plants across India — well, three operational after the Hyderabad fire tragedy in June 2025.
Investors now wait to see if Sigachi can rebuild credibility faster than it built its MCC reactors.
2. Introduction
There’s bad luck, and then there’s Sigachi 2025.
June 2025 will go down in the company’s history as the day when its Hyderabad plant suffered a devastating dust explosion, killing 46 employees, injuring 25, and halting operations for over six months. It wasn’t just a plant fire — it was an existential test. Production, reputation, and investor faith all went up in literal smoke.
But Sigachi did something unusual for smallcaps — it faced the crisis transparently. From ex-gratia payouts to families (₹5.8 crore), to insurance filings and safety audits, the company communicated more than most in its segment.
Operationally, it shifted production to Dahej and Jhagadia plants and even expanded capacity by 12,000 MTPA at Dahej SEZ to offset the Hyderabad loss. This kind of damage control deserves credit — but make no mistake, financially, FY26 will look like a crime scene for margins.
The company’s stock now trades at 24.5x P/E, a valuation that assumes this was a one-off disaster, not a chronic problem. But with 39.6% promoter pledging and shrinking promoter stake (down 3.6% QoQ), it’s fair to ask: has the market forgiven too soon?
3. Business Model – WTF Do They Even Do?
Sigachi manufactures Microcrystalline Cellulose (MCC) — a fine powder that pharmaceutical, nutraceutical, and food companies use as an excipient (basically, the filler that keeps your tablet together). If APIs are the actors, Sigachi makes the glue and set design.
Here’s the buffet of their product mix:
MCC (80%) – the flagship cellulose excipient, with 60+ grades.
APIs & Intermediates (7%) – via subsidiary Trimax.
Operations & Management Services (10%) – technical consulting for global partners.
Allied trades (3%) – packaging, vitamins, and blends.
Sigachi’s customer list reads like a chemist’s dream: global pharma giants, nutraceutical makers, and food companies across 65+ countries. About 66% of revenue comes from exports — mostly the US, EU, and MENA markets.
They’re now betting on diversification:
Trimax acquisition (80% stake) – an API/intermediates unit expanding to 250 KL capacity by Jan 2026.
Cross Carmellose Sodium (CCS) project at Dahej (₹90 Cr) – for super-disintegrants (the stuff that makes tablets break apart faster).
Subsidiaries in the USA, UK, and MENA, with new JVs in Sigachi Arabia and Sigachi Global.
The business model is half pharmaceutical, half chemical engineering — and all dependent on one thing: safety and compliance. Because one more explosion, and no ESG rating can save this balance sheet.
4. Financials Overview
Source table
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue
₹110 Cr
₹125 Cr
₹128 Cr
-12%
-14%
EBITDA
₹8 Cr
₹17 Cr
₹24 Cr
-53%
-66%
PAT
₹6.3 Cr
₹21 Cr
₹-101 Cr (fire loss)
-71%
N.A.
EPS (₹)
0.28
0.64
-2.63
-56%
N.A.
Commentary: The fire’s financial aftertaste lingers — EBITDA collapsed 66% sequentially. Operating margin at 7% (vs. 22% YoY) shows how one factory shutdown can kneecap the entire business. The fact that they still posted a positive PAT shows exceptional insurance or cost-cutting discipline.
5. Valuation Discussion – Fair Value Range (Educational Only)
Let’s put the post-crisis math to work.
(a) P/E Method: Annualised EPS (assuming post-fire normalization) = ₹0.28 × 4 = ₹1.12 Industry average P/E ≈ 32x (Pharma smallcaps) Fair Value Range = ₹36 – ₹48
(b) EV/EBITDA Method: FY25 EBITDA = ₹100 Cr EV/EBITDA multiple = 12–15x Fair Enterprise Value = ₹1,200–₹1,500 Cr Subtract Net Debt (₹145 Cr) → Equity Value ≈ ₹1,050–₹1,350 Cr Per share fair range ≈ ₹28–₹36
🎯 Educational Fair Value Range: ₹30 – ₹45 (This fair value range is for educational purposes only and is not investment advice.)
6. What’s Cooking – News, Triggers, Drama
Fire Aftermath: The June 30, 2025 dust explosion killed 46 workers and caused a ₹116 Cr loss. Hyderabad plant shut for 180 days. Operations temporarily shifted to Dahej and Jhagadia.
Expansion Amid Chaos: Despite the tragedy, Sigachi added 12,000 MTPA MCC capacity at Dahej SEZ, bringing total to 30,000 MTPA — a move that signals business continuity under pressure.
Trimax Expansion: Capacity expansion by 150 KL to reach 250 KL by Jan 2026; targeting regulated markets with 4 CEPs filed.
